| abstract |
The invention relates to novel imidazolidine-type compounds of the formula I in which R1 to R7 have the meanings given in the claims. These compounds represent potential inhibitors of sodium / hydrogen exchange (NHE), and in particular NHE. They are used to produce a drug for the treatment or prophylaxis of the central nervous system, disorders of fat metabolism, conditions caused by ectoparasites, disorders of bile function, as well as to improve respiratory drive and are therefore used to treat respiratory functions in the following clinical conditions and diseases: impairment of central respiratory function (eg central sleep apnea, sudden infant death, postoperative hypoxia), respiratory disturbances caused by musculature, respiratory disturbances of patients after prolonged artificial administration of oxygen or air through their respiratory organs, respiratory distress in adaptation plans , for the treatment of obstructive and mixed forms of sleep apnea, acute and chronic lung diseases with hypoxia and hypercapnia. In addition, these compounds increase the muscle tone of the upper respiratory tract, so that they suppress the appearance of snoring. |